Screening Test Evaluation — Evaluating Screening Tests and Programs

A diagnostic accuracy study assesses test performance in patients who already have symptoms or clinical suspicion of a condition. Screening test evaluation is applied to asymptomatic or general populations and adds program-level considerations — prevalence effects on predictive values, lead-time and length-time bias, overdiagnosis, coverage, and cost-effectiveness. Both use the same core metrics (sensitivity, specificity, AUC), but the context, study design, and interpretation differ substantially.

In a low-prevalence population, even a test with 95% specificity will generate many false positives because the majority of the population is truly negative. PPV tells patients and clinicians the probability that a positive test result reflects true disease — which is what matters clinically. A test with 90% sensitivity and 90% specificity applied to a population with 1% prevalence yields a PPV of only about 8%; nine out of ten positives would be false alarms.

Lead time is the interval between screen-detected diagnosis and the time the disease would have been diagnosed clinically due to symptoms. If survival is measured from diagnosis, screened patients appear to survive longer even if they die at the same time as unscreened patients — their apparent longer survival is merely an artifact of earlier detection, not a true benefit. Evaluations must use disease-specific mortality in the screened versus control population, not survival from diagnosis, to avoid this bias.

There is no universally optimal threshold — the choice depends on the relative clinical and social costs of false positives and false negatives. Common approaches include the Youden index (maximizes sensitivity + specificity − 1), cost-benefit analysis weighting the two error types, or selecting a fixed sensitivity (e.g., 90%) first and then reading off the corresponding specificity. For serious conditions where missing a case is catastrophic, a high-sensitivity threshold is usually preferred even at the cost of more false positives.

The Wilson-Jungner criteria are ten conditions proposed in the 1968 WHO report that should be met before a population screening program is introduced. Key criteria include: the condition should be an important health problem; there should be an accepted treatment for detected disease; facilities for diagnosis and treatment must be available; there should be a recognizable latent or early symptomatic stage; a suitable test or examination must exist; the test must be acceptable to the population; the natural history of the condition should be understood; and the cost should be balanced against the overall expenditure on medical care. These criteria remain foundational to screening policy worldwide.